Table V.
OS | DFS | |||||
---|---|---|---|---|---|---|
|
|
|||||
Characteristics | HR | 95% CI | P | HR | 95% CI | P-value |
p85α overexpression vs. downregulation | 3.06 | 1.13–8.31 | 0.028 | 2.68 | 1.30–5.54 | 0.008 |
miR-21 low vs. high | 2.47 | 1.08–5.65 | 0.033 | 1.80 | 1.03–3.12 | 0.038 |
Clinical stage I vs. II vs. III | 4.20 | 2.15–8.20 | <0.001 | 3.59 | 2.35–5.50 | <0.001 |
Tumor size (cm) ≤2 vs. >2 | 3.44 | 1.28–9.27 | 0.015 | 3.82 | 1.95–7.46 | <0.001 |
Node negative vs. positive | 5.38 | 2.00–14.45 | 0.001 | 3.76 | 2.02–6.98 | <0.001 |
Histological grade 1 vs. 2 vs. 3 | 2.57 | 1.19–5.55 | 0.017 | 2.25 | 1.47–3.45 | <0.001 |
Subtypes of breast cancer | 1.25 | 0.77–2.04 | 0.371 | 1.01 | 0.72–1.43 | 0.944 |
ER negative vs. positive | 0.63 | 0.25–1.59 | 0.327 | 0.95 | 0.46–1.97 | 0.891 |
PR negative vs. positive | 0.96 | 0.36–2.58 | 0.933 | 1.19 | 0.57–2.46 | 0.646 |
HER2 negative vs. positive | 0.70 | 0.20–2.39 | 0.577 | 0.99 | 0.48–2.07 | 0.991 |
Mastectomy vs. breast conservation | 0.50 | 0.26–0.95 | 0.033 | 0.63 | 0.42–0.95 | 0.026 |
Neoadjuvant chemotherapy vs. adjuvant chemotherapy vs. not given | 0.33 | 0.05–2.48 | 0.282 | 0.55 | 0.20–1.52 | 0.246 |
Italics indicate significance.
Sample sizes differ due to complete data set per Cox model.